ATE520032T1 - Differentielle cytokinexpression bei einer menschlichen krebserkrankung - Google Patents

Differentielle cytokinexpression bei einer menschlichen krebserkrankung

Info

Publication number
ATE520032T1
ATE520032T1 AT07764767T AT07764767T ATE520032T1 AT E520032 T1 ATE520032 T1 AT E520032T1 AT 07764767 T AT07764767 T AT 07764767T AT 07764767 T AT07764767 T AT 07764767T AT E520032 T1 ATE520032 T1 AT E520032T1
Authority
AT
Austria
Prior art keywords
human cancer
cytokine expression
differential cytokine
differential
expression
Prior art date
Application number
AT07764767T
Other languages
English (en)
Inventor
Giorgio Stassi
Christian Gieffers
Oliver Hill
Meinolf Thiemann
Matilde Todaro
Original Assignee
Apogenix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogenix Gmbh filed Critical Apogenix Gmbh
Application granted granted Critical
Publication of ATE520032T1 publication Critical patent/ATE520032T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07764767T 2006-06-21 2007-06-21 Differentielle cytokinexpression bei einer menschlichen krebserkrankung ATE520032T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06012754 2006-06-21
PCT/EP2007/005480 WO2007147600A2 (en) 2006-06-21 2007-06-21 Differential il-4 and/or il-10 cytokine expression in human cancer

Publications (1)

Publication Number Publication Date
ATE520032T1 true ATE520032T1 (de) 2011-08-15

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07764767T ATE520032T1 (de) 2006-06-21 2007-06-21 Differentielle cytokinexpression bei einer menschlichen krebserkrankung

Country Status (12)

Country Link
US (1) US20090324616A1 (de)
EP (1) EP2041576B1 (de)
JP (1) JP2010514409A (de)
CN (1) CN101529253A (de)
AT (1) ATE520032T1 (de)
AU (1) AU2007263265A1 (de)
BR (1) BRPI0713484A2 (de)
CA (1) CA2656379A1 (de)
DK (1) DK2041576T3 (de)
ES (1) ES2371287T3 (de)
RU (1) RU2009101783A (de)
WO (1) WO2007147600A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
CA2878992C (en) * 2012-07-18 2020-09-22 Apogenix Gmbh Composition comprising a mixture of cd95-fc isoforms
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
SG11201703326SA (en) * 2014-10-24 2017-05-30 Aladar Szalay Combination immunotherapy approach for treatment of cancer
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
DK3389696T3 (da) 2015-12-17 2024-12-16 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
US20190317098A1 (en) * 2016-11-24 2019-10-17 Huvet Bio, Inc. Composition for diagnosis of diseases
AU2018327225A1 (en) * 2017-09-06 2020-02-27 Fred Hutchinson Cancer Center Strep-tag specific chimeric receptors and uses thereof
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
AP583A (en) 1993-09-07 1997-04-14 Smithkline Beecham Corp Recombination IL4 antibodies useful in treatment of IL4 mediated disorders.
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
EP1013764A1 (de) * 1994-07-05 2000-06-28 Steeno Research Group A/S Immunomodulatoren
CN1117155C (zh) * 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
EP1029550A4 (de) * 1997-11-10 2001-09-26 Mochida Pharm Co Ltd Vorbeugende mittel und heilmittel gegen diffuse lungenkrankheiten
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
CN1441677A (zh) * 2000-03-31 2003-09-10 Idec药物公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20040023337A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
EP1444989A1 (de) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisierung von Zellen für die Apoptose durch selektive Blockade von Zytokinen
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
JP2008520684A (ja) * 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy

Also Published As

Publication number Publication date
DK2041576T3 (da) 2011-12-05
JP2010514409A (ja) 2010-05-06
AU2007263265A1 (en) 2007-12-27
RU2009101783A (ru) 2010-07-27
WO2007147600A2 (en) 2007-12-27
US20090324616A1 (en) 2009-12-31
EP2041576A2 (de) 2009-04-01
ES2371287T3 (es) 2011-12-29
CA2656379A1 (en) 2007-12-27
BRPI0713484A2 (pt) 2012-11-06
EP2041576B1 (de) 2011-08-10
WO2007147600A3 (en) 2008-04-10
CN101529253A (zh) 2009-09-09

Similar Documents

Publication Publication Date Title
ATE520032T1 (de) Differentielle cytokinexpression bei einer menschlichen krebserkrankung
GB2566371A (en) Methods and systems for collecting spirometry data
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
MX2015002289A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso.
MX2013001362A (es) Inmunoglubinas de dominio variable doble y usos de las mismas.
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
UA101301C2 (ru) ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
JO3182B1 (ar) مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
GB2478065A (en) Method and systems for personalized action plans
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
BRPI0811581A2 (pt) Estimuladores de sgc, ativadores de sgc e combinações para o tratamento de distúrbios urológicos
ATE554396T1 (de) Diagnose- und therapiewerkzeuge für krankheiten, die die gefässfunktion verändern
WO2012145535A3 (en) Animal model of human cancer and methods of use
WO2007109733A3 (en) Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
UY29777A1 (es) Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión.
Armitage AAP centennial commentary: theme 3: Evolution and application of classification systems for periodontal diseases--a retrospective commentary
WO2012005719A3 (en) Oral health index
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness
MX2009011388A (es) Inhibidores de polimerasa y su uso para el tratamiento de tumores.
ATE489947T1 (de) Axomadol zur schmerzbehandlung bei arthrose
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties